

Dimeric mimetic of BDNF loop 4 promotes survival of serum-deprived cell through TrkB-dependent apoptosis suppression

L.F. Zainullina [§], Yu.V. Vakhitova ^{§*}, A.Yu. Lusta, T.A. Gudasheva, S.B. Seredenin
*Federal State Budgetary Institution «Research Zakusov Institute of Pharmacology»,
Moscow, Russia*

[§]authors contributed equally to this work.

***Correspondence:** Vakhitova Yulia, vakhitova@academpharm.ru; Department of Pharmacogenetics, «Research Zakusov Institute of Pharmacology»,
Baltiyskaya str., 8, Moscow, 125315, Russia

Supplementary Info File

Data availability statement: All the original data acquisition of western blots is included in Supplementary Info file.


Keywords: BDNF, low weight mimetics, TrkB signaling, neuroprotection, BAD, GSK-3 β

Supplementary Figure Legend


Supplementary Figure 1. (A) MEK1 inhibitor (PD98059) had no effect on Akt pathway. SH-SY5Y cells in serum-free culture medium («0% FBS») with or without BDNF (~ 1 nmol) or GSB-106 (100 nmol) were also pre incubated with or without PD98059 (50 µmol, 60 min). Blots were first probed with anti-phosphorylated pan-Akt (pAkt1/2/3) antibody and then reprobed with anti-pan-Akt antibody, anti- α -tubulin antibody. The figure shows data from one independent experiment (n=3; the original blots are shown in the supplementary information file).

(B) PI3K inhibitor (LY294002) had no effect on MAPK pathway. SH-SY5Y cells in serum-free culture medium («0% FBS») with or without BDNF (~ 1 nmol) or GSB-106 (100 nmol) were also pre incubated with or without LY290042 (50 µmol, 60 min). Blots were first probed with anti-phosphorylated Erk (pErk) antibody and then reprobed with anti-Erk antibody, anti- α -tubulin antibody. The figure shows data from one independent experiment (n=3; the original blots are shown in the supplementary information file).

Zainullina et al., Supplementary Figure 1



Figures with relative original data acquisition










Zainullina et al., Figure 1

Original scans of blots, corresponding to figure 1B

Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.

B






Zainullina et al., Figure 3

Original scans of blots, corresponding to figure 3A

Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.



Zainullina et al., Figure 3


Original scans of blots, corresponding to figure 3C


Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.



Zainullina et al., Figure 3

Original scans of blots, corresponding to figure 3E






Zainullina et al., Figure 4

Original scans of blots, corresponding to figure 4A


Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.



Zainullina et al., Figure 4

Original scans of blots, corresponding to figure 4D




Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.



Zainullina et al., Figure 4

Original scans of blots, corresponding to figure 4E





Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.









Zainullina et al., Figure 4

Original scans of blots, corresponding to figure 4F

Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.








Zainullina et al., Figure 5





Original scans of blots, corresponding to figure 5A

Blots acquired on X-film. TIFF files are available.



Original scans of blots, corresponding to figure 5C


Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.



Zainullina et al., Figure 5

Original scans of blots, corresponding to figure 5C (continued)


Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.




Zainullina et al., Figure 5

Original scans of blots, corresponding to figure 5D

Blots acquired on Amersham Imager 680 (GE HealthCare).
TIFF files are available.







Zainullina et al., Figure 6

Original scans of blots, corresponding to figure 6A and 6E


Blots acquired on a Alliance Q9 gel documentation system (UVITEC).
TIFF files are available.




Before of transformation correction




Blots acquired on X-film. TIFF files are available.



Before of GrayScale and horizontal transformation correction



After GrayScale correction




anti-Caspase-9 Antibody (1:1000, #9502, Cell Signaling Technology)

anti-Caspase-9 Antibody (1:1000, #9502, Cell Signaling Technology)

anti-α-Tubulin (1:1000, #2125, Cell Signaling Technology)

anti-α-Tubulin (1:1000, #2125, Cell Signaling Technology)

Zainullina et al., Supplementary Figure 1 as submitted



Zainullina et al., Supplementary Figure 1

Original scans of blots, corresponding to Supplementary Figure 1A and 1B

